Clinical Trials
48 trialsPRESERVE-009
OncoC4, Inc.
MAST
Imugene Limited
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
AMPLIFY-201
Elicio Therapeutics
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Leap Therapeutics, Inc.
PIPAC-NAL-IRI
University Hospital, Ghent
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
Shanghai Bao Pharmaceuticals Co., Ltd.
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
DUET-2
Xencor, Inc.
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
Karolinska University Hospital
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Curegenix Inc.
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
PCI Biotech AS
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Vanderbilt-Ingram Cancer Center
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Mayo Clinic
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Mayo Clinic
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
University of Pittsburgh
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
City of Hope Medical Center
Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer
Akita University Hospital
Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer
City of Hope Medical Center
Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
University of Southern California
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Memorial Sloan Kettering Cancer Center
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Metastatic Cancer
Duke University
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Cancer in the Abdomen
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
National Institutes of Health Clinical Center (CC)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
UNC Lineberger Comprehensive Cancer Center
Gene Therapy in Treating Patients With Cancer
Roger Williams Medical Center
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NYU Langone Health
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
NYU Langone Health
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center